MOG encephalomyelitis: international recommendations on diagnosis and antibody testingSven Jarius, Brigitte Wildemann, Friedemann Paul et al.|Journal of Neuroinflammation|2018Cited by 740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Neuromyelitis opticaSven Jarius, Brigitte Wildemann, Friedemann Paul et al.|Nature Reviews Disease Primers|2020Cited by 464
Update on biomarkers in neuromyelitis opticaEsther Melamed, Danielle van Pelt, Michael Levy et al.|Neurology Neuroimmunology & Neuroinflammation|2015Cited by 119
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodiesKimihiko Kaneko, Masashi Aoki, Douglas Kazutoshi Sato et al.|Journal of Neurology Neurosurgery & Psychiatry|2016Cited by 108